Elmer, what did you make of the second EPO cohort data? I thought the response rate was very promising, and given it allows dosage 1x monthly there are real benefits for doctor and patient. I'm hoping we get good news on the results of the third cohort quite soon, where they will have figured out the optimum dosage. If that looks like it's showing a response rate in the 90s (up from 75) then we have a very valuable compound on our hands.

Suspect Scott will nail out a pretty good deal for shareholders to out-license, it tends to be his strength!